Search Results

The role of mitochondrial dysfunction in the cytotoxic synergistic effect of gemcitabine and arsenic on breast cancer.

• Authors : Maleki F; Faculty of Medical Sciences, Department of Toxicology, Tarbiat Modares University, Tehran, Iran.; Handali S

Subjects: Gemcitabine* ; Deoxycytidine*/Deoxycytidine*/Deoxycytidine*/analogs & derivatives ; Deoxycytidine*/Deoxycytidine*/Deoxycytidine*/pharmacology

• Source: PloS one [PLoS One] 2025 Jan 07; Vol. 20 (1), pp. e0312424. Date of Electronic Publication: 2025 Jan 07 (Print Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet

Record details

pH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant K-Ras-addicted pancreatic cancer cells and mouse model.

• Authors : Dutta D; Department of Coatings and Polymeric Materials, North Dakota State University, Fargo, ND, United States of America.; Ray P

Subjects: Deoxycytidine*/Deoxycytidine*/Deoxycytidine*/analogs & derivatives ; Deoxycytidine*/Deoxycytidine*/Deoxycytidine*/pharmacology ; Deoxycytidine*/Deoxycytidine*/Deoxycytidine*/administration & dosage

• Source: PloS one [PLoS One] 2024 Apr 30; Vol. 19 (4), pp. e0297749. Date of Electronic Publication: 2024 Apr 30 (Print Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet

Record details

Fluoropyrimidine combination therapy versus fluoropyrimidine monotherapy for gemcitabine-refractory advanced pancreatic cancer: A systematic review and meta-analysis of randomized controlled trials.

• Authors : Tian W; Department of Oncology III, Zibo Central Hospital, Shandong University, Zibo, Shandong, Peoples' Republic of China.; Zhang L

Subjects: Gemcitabine* ; Pancreatic Neoplasms*/Pancreatic Neoplasms*/Pancreatic Neoplasms*/drug therapy; Humans

• Source: PloS one [PLoS One] 2023 Mar 02; Vol. 18 (3), pp. e0282360. Date of Electronic Publication: 2023 Mar 02 (Print Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet

Record details

Risk factors for severe neutropenia in pancreatic cancer patients treated with gemcitabine/nab-paclitaxel combination therapy.

• Authors : Ito G; Division of Drug Informatics, Keio University Faculty of Pharmacy, Tokyo, Japan.; Kawakami K

Subjects: Pancreatic Neoplasms*/Pancreatic Neoplasms*/Pancreatic Neoplasms*/drug therapy ; Gemcitabine* ; Deoxycytidine*/Deoxycytidine*/Deoxycytidine*/analogs & derivatives

• Source: PloS one [PLoS One] 2021 Jul 14; Vol. 16 (7), pp. e0254726. Date of Electronic Publication: 2021 Jul 14 (Print Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet

Record details

Electrophysiological evaluation of an anticancer drug gemcitabine on cardiotoxicity revealing down-regulation and modification of the activation gating properties in the human rapid delayed rectifier potassium channel.

• Authors : Wei, Mengyan; Wang, Pu; Zhu, Xiufang

Subjects: POTASSIUM channels; ANTINEOPLASTIC agents; GEMCITABINE

• Source: PLoS ONE; 2/2/2023, Vol. 17 Issue 2, p1-22, 22p

Record details

Ataxia telangiectasia and Rad3-related inhibition by AZD6738 enhances gemcitabine-induced cytotoxic effects in bladder cancer cells

• Authors : Isono, Makoto; Okubo, Kazuki; Asano, Takako

• Source: PLoS ONE. April 12, 2022, Vol. 17 Issue 4, e0266476

Record details

Early detection of venous thromboembolism after the initiation of chemotherapy predicts a poor prognosis in patients with unresectable metastatic pancreatic cancer who underwent first-line chemotherapy with gemcitabine plus nab-paclitaxel

• Authors : Yamai, Takuo; Ikezawa, Kenji; Hiraga, Erika

• Source: PLoS ONE. March 1, 2022, Vol. 17 Issue 3, e0264653

Record details

Gemcitabine-induced Gli-dependent activation of hedgehog pathway resists to the treatment of urothelial carcinoma cells.

• Authors : Chang, Yu-Hao¹ (AUTHOR); Tam, Hoi-Lam¹ (AUTHOR); Lu, Meng-Chien¹ (AUTHOR)

Subjects: *TRANSITIONAL cell carcinoma; *GEMCITABINE

• Source: PLoS ONE. 7/8/2021, Vol. 16 Issue 7, p1-15. 15p.

Record details

Cytoplasmic RRM1 activation as an acute response to gemcitabine treatment is involved in drug resistance of pancreatic cancer cells.

• Authors : Kato, Tomotaka; Ono, Hiroaki; Fujii, Mikiya

Subjects: DRUG resistance in cancer cells; OVERALL survival; DNA repair

• Source: PLoS ONE; 6/10/2021, Vol. 16 Issue 6, p1-17, 17p

Record details

Progesterone receptor expression contributes to gemcitabine resistance at higher ECM stiffness in breast cancer cell lines.

• Authors : Grant, Emma; Bucklain, Fatma A.; Ginn, Lucy

Subjects: PROGESTERONE receptors; CELL lines; BREAST cancer

• Source: PLoS ONE; 5/26/2022, Vol. 17 Issue 5, p1-16, 16p

Record details